Topics

Syros Pharmaceuticals, Inc. Company Profile

16:23 EDT 20th September 2019 | BioPortfolio

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and immune-mediated diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid tumors, including transcriptionally dependent cancers such as triple negative breast, small cell lung and ovarian cancers. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.


News Articles [860 Associated News Articles listed on BioPortfolio]

Santhera’s Syros succesful in DMD study

Santhera Pharmaceuticals has announced results from its Syros DMD study.

Syros Announces Pricing of US$70 Million Concurrent Public Offerings

Syros Pharmaceuticals (NASDAQ:SYRS) has announced it has priced its concurrent underwritten public offering of 8.6 million shares of its common stock and accompanying Class A warrants to purchase up t...

Checking In On Syros Pharmaceuticals

Syros Pharmaceuticals Platform Undervalued After Dip

Syros Pharmaceuticals (SYRS) Investor Presentation - Slideshow

Syros Pharmaceuticals, Inc. 2019 Q2 - Results - Earnings Call Slides

Syros to Present at 2019 Wedbush PacGrow Healthcare Conference

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Financial Officer, Joseph J. Ferra, will present a c...

Syros to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. E...

Drugs and Medications [0 Results]

None

PubMed Articles [137 Associated PubMed Articles listed on BioPortfolio]

Mytilidae as model organisms in the marine ecotoxicology of pharmaceuticals - A review.

Growing production and consumption of pharmaceuticals is a global problem. Due to insufficient data on the concentration and distribution of pharmaceuticals in the marine environment, there are no app...

Occurrence and ranking of pharmaceuticals in the major rivers of China.

Residual pharmaceuticals have received widespread attention worldwide due to their continuous release and potential hazard to the environment. As a result of rapid development and a large population, ...

Occurrence and distribution of pharmaceuticals in raw, finished, and drinking water from seven large river basins in China.

The occurrence of pharmaceuticals in the drinking water is a growing concern in China. In this study, we determined the concentration and distribution of 59 selected pharmaceuticals in raw, finished, ...

U.S. Emergency Department Visits Resulting From Nonmedical Use of Pharmaceuticals, 2016.

National data on morbidity from nonmedical use of pharmaceuticals are limited. This study used nationally representative, public health surveillance data to characterize U.S. emergency department visi...

Simultaneous aqueous chlorination of amine-containing pharmaceuticals.

Amine-containing pharmaceuticals such as acetaminophen, diclofenac, and sulfamethoxazole are the most often detected pharmaceuticals in wastewater and other aquatic environments. Amine-containing phar...

Clinical Trials [244 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1383 Associated Companies listed on BioPortfolio]

Syros Pharmaceuticals

Syros Pharmaceuticals is a life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Syros’ proprietary plat...

Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. S...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Serenity Pharmaceuticals

Founded in 2007 and located in Milford, Pennsylvania, Serenity Pharmaceuticals is focused on developing products that address urinary conditions that impact the health and well-be...

More Information about "Syros Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of Syros Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Syros Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Syros Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Syros Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Syros Pharmaceuticals, Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record